相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件:
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year
- 保质期:
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year
- 英文名:
BMS-833923
- 库存:
现询
- 供应商:
北京索莱宝科技有限公司
- CAS号:
1059734-66-5
- 规格:
100mg/50mg/10mg/5mg
| 规格: | 100mg | 产品价格: | ¥2590.0 |
|---|---|---|---|
| 规格: | 50mg | 产品价格: | ¥1590.0 |
| 规格: | 10mg | 产品价格: | ¥704.0 |
| 规格: | 5mg | 产品价格: | ¥436.0 |
是Smoothened抑制剂,有抗肿瘤活性。
| 基本信息 | |
| CAS | No.1059734-66-5 |
| 英文名称 | BMS-833923 |
| 别名 | XL139 |
| 分子式 | C30H27N5O |
| 分子量 | 473.57 |
| 溶解性 | Soluble in DMSO ≥5mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | Light yellow to yellow Solid |
| 储存条件 | Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
| MDL | MFCD25976660 |
| SMILES | O=C(NC1=CC(CNC)=CC=C1C)C2=CC=C(NC3=NC(C4=CC=CC=C4)=C5C=CC=CC5=N3)C=C2 |
| InChIKey | KLRRGBHZCJLIEL-UHFFFAOYSA-N |
| InChI | InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35) |
| PubChem CID | 57662985 |
| 靶点 | Smo |
| 通路 | Hedgehog;Stem Cells |
| 背景说明 | 是Smoothened抑制剂,有抗肿瘤活性。 |
| 生物活性 | BMS-833923 (XL-139) is an orally bioavailable small-molecule inhibitor of Smoothened with potential antineoplastic activity; inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM.[1] |
| IC50 | IC50: 6-35 nM [1] |
| In Vitro | BMS-833923 inhibits the expression of downstream effectors in the HH pathway (GLI1 and PTCH1) in cell lines that express wild-type SMO and those which express activated mutant forms of SMO (IC50values of 6-35 nM). In FACS-based binding assays, BMS-833923 inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM [1]. |
| 细胞实验 | Pharmacodynamic studies show that BMS-833923 robustly inhibits HH pathway activity with along duration of action after a single oral dose in medulloblastoma and pancreatic carcinoma xenograft models.The pharmacodynamic effects of BMS-833923 observed in these models translate into tumor growth inhibition at well-tolerated doses [1]. |
| 数据来源文献 | [1]. Steven B, et al. Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics: December 2009; Volume 8, Issue 12, Supplement 1. |
| 单位 | 瓶 |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IB2030 BMS-833923 抑制剂/拮抗剂/激动剂 索莱宝
¥436 - 2590










